This Peer Exchange® centers on navigating the complexities of drug pricing, market access, and reimbursement through the balance of regulatory, payer, and patient perspectives using modern innovative approaches, partnerships, and technologies.
Advertisement
Advertisement
Trending on PharmExec
1
Aradhana Sarin: The CFO as a Catalyst
2
Regeneron Enters $2.1 Billion Radiopharma Collaboration with Telix Pharmaceuticals
3
Pharmaceutical Executive Daily: FDA Issues Second CRL for Replimune's RP1 Melanoma Treatment
4
FDA Issues CRL to Replimune for RP1 Biologics License Application for Advanced Melanoma Treatment
5